Therapy Areas: Diabetes
American Diabetes Association's clinical trial finds dapagliflozin was well tolerated in hospitalised COVID-19 patients
28 June 2021 -

Healthcare company American Diabetes Association reported on Sunday the launch of the first large randomised clinical trial DARE-19 to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19.

Dr Mikhail Kosiborod, Cardiologist and Vice President for Research at Saint Luke's Health System, Professor of Medicine, University of Missouri-Kansas City presented his findings at the virtual 81st Scientific Sessions.

DARE-19 is an investigator-sponsored, international, randomized trial and compared SGLT2 inhibitor dapagliflozin to placebo in 1,250 patients hospitalised for COVID-19 with hypertension, atherosclerotic cardiovascular disease, heart failure, type 2 diabetes and chronic kidney disease. Patients with cardiometabolic risk factors, including type 2 diabetes, are at higher risk for developing serious COVID-19 related complications such as organ failure and death.

The patients were recruited across 95 centres in seven countries between April 2020 and January 2021. Patients received dapagliflozin or placebo for 30 days in addition to the standard of care for COVID-19 in the participating hospital. Treatment with dapagliflozin did not achieve statistically significant reduction in organ failure or death, or significantly improve clinical recovery, as compared with placebo.

In conjunction, the company said future trials are needed to evaluate possible effects of dapagliflozin on the risk of organ failure or death in patients hospitalised with COVID-19. DARE-19, which was funded by AstraZeneca, has important implications for future research.